Latest Content

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.

Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.

Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.